CHO-K1/Human DP2 Stable Cell
Item | Cat# | Price |
Stable Cell Line | SNB-G-0195A | $19,800 |
Compound Testing Services | CT-001 | $1,850 per 384w plate (Up To 16 cpds Dose) |
Product Description
The DP2 receptor (Prostaglandin D2 receptor 2), also known as CRTH2, is a G protein-coupled receptor encoded by the PTGDR2 gene. It is primarily expressed on immune cells such as Th2 lymphocytes, eosinophils, basophils, and group 2 innate lymphoid cells. Upon activation by prostaglandin D2, it couples to Gi proteins to inhibit cAMP production and increase calcium influx, thereby inducing chemotaxis, activation, and pro-inflammatory cytokine release from type 2 immune cells, playing a pivotal role in initiating and perpetuating allergic inflammation (e.g., asthma, atopic dermatitis). This receptor has emerged as an important therapeutic target for allergic diseases; however, due to complex signaling bias mechanisms, related antagonists remain under clinical development.
Screeningbio’s CHO-K1/Human DP2 cell line overexpress PTGDR2 and is designed to detect inhibition in intracellular cAMP levels in response to agonist stimulation of the receptor. Cisbio HTRF cAMP kit can be used to detect the signal.
Product Specifications
Target Type | GPCR |
Species | Human |
HGNC Symbol | PTGDR2 |
Accession Number | NM_004778 (Hs) |
Parental Line | HEK293 |
Lot# | See Vial |
Storage | Liquid Nitrogen |
Data
Target Background
The DP2 receptor (Prostaglandin D2 receptor 2), also known as CRTH2, is a G protein-coupled receptor encoded by the PTGDR2 gene.
It is primarily expressed on immune cells such as Th2 lymphocytes, eosinophils, basophils, and group 2 innate lymphoid cells. Upon activation by prostaglandin D2, it couples to Gi proteins to inhibit cAMP production and increase calcium influx, thereby inducing chemotaxis, activation, and pro-inflammatory cytokine release from type 2 immune cells, playing a pivotal role in initiating and perpetuating allergic inflammation (e.g., asthma, atopic dermatitis).
This receptor has emerged as an important therapeutic target for allergic diseases; however, due to complex signaling bias mechanisms, related antagonists remain under clinical development.